O
ver the past decade, the discovery of mutations in genes encoding ion channels (1) has helped researchers to better understand the mechanism of the congenital long QT syndrome, an inherited disease characterized by prolonged ventricular repolarization and a propensity for life-threatening ventricular tachyarrhythmias resulting in syncope and sudden death (2) . Current estimates suggest that 1 in 10 000 persons are gene carriers and that the congenital long QT syndrome causes 3000 to 4000 sudden deaths in children and young adults each year in the United States (3). The two major clinical syndromes characterized on the basis of the genetic transmission pattern are a more common autosomal-dominant form (the Romano-Ward syndrome) with a pure cardiac phenotype (4, 5) and a rarer autosomal-recessive form (the Jervell and Lange-Nielsen syndrome) characterized by the association with congenital neuronal deafness (6) . The congenital long QT syndrome occurring secondary to electrolyte disturbances or drug therapy is called the acquired long QT syndrome (7) .
As a consequence of the genetic information, it became clear that what has been classified under the unifying name "long QT syndrome" actually represents many different diseases caused by ion channel mutations; these mutations produce alterations in ionic currents, leading to the same result: prolonged ventricular repolarization (8) . In addition, the first ion channel gene mutations and polymorphisms that predispose people to drug-provoked QT interval prolongation and ventricular arrhythmias have been identified (9, 10) .
In this review, we classify the forms of the congenital long QT syndrome; discuss the proposed explanations of the cellular electrophysiology of the syndrome; review the clinical characteristics of the syndrome; and discuss the identification and management of patients with the congenital long QT syndrome, including novel approaches, such as genotype-specific therapies.
METHODS
We searched the PubMed database for literature on the congenital long QT syndrome, focusing on advances in four areas: forms of the congenital long QT syndrome, explanations of the cellular electrophysiology of the syndrome, clinical characteristics of the syndrome, and identification and management of patients with the congenital form of the syndrome. We manually extracted, classified, and summarized data from peer-reviewed studies.
GENETICS OF THE CONGENITAL LONG QT SYNDROME
Genetic linkage mapping of the autosomal-dominant Romano-Ward syndrome has so far identified loci on six chromosomes (LQT1 to LQT6 ) (11) (12) (13) (14) (15) (16) (17) . The autosomalrecessive variant (the Jervell and Lange-Nielsen syndrome) arises in individuals who inherit abnormal KCNQ1 (ϭ KvLQT1) or KCNE1 (ϭ minK ) alleles from both parents (LQT1, LQT5). The abnormal gene can be the same (usually in consanguineous families) or different (so-called compound heterozygosity) (18) . Parents of individuals with the Jervell and Lange-Nielssen syndrome are heterozygous for long QT syndrome mutations but are usually (but not always) asymptomatic (19) . Most long QT syndrome genes encode K ϩ channels; the exception is the LQT3 gene (SCN5A), which encodes the cardiac Na ϩ channel (current indicated by I Na ) (20) . Mutations in either the ␣-subunit encoded by KCNQ1 (LQT1) or the ␤-subunit encoded by KCNE1 (LQT5) can cause defects in the I Ks current. Similarly, mutations in the LQT2 (KCNH2 ϭ HERG) and LQT6 (KCNE2 ϭ MiRP1) genes encoding the ␣-and ␤-subunits of the rapidly activating delayed rectifier K ϩ channel I Kr , respectively, may cause the congenital long QT syndrome (17) .
FUNCTIONAL CONSEQUENCES OF THE CONGENITAL LONG QT SYNDROME MUTATIONS
The channels carrying the I Ks and I Kr potassium currents are multimeric (15, 16) ; alleles from both parents are thought to contribute to the channel complexes (21) . By using heterologous expression systems such as Xenopus oocytes or mammalian cell lines, mutations in KCNQ1, KCNE1, KCNH2, or KCNE2 expressed alone or in combination with wild-type alleles typically exhibit a "loss of function" (Figure 1 ). The total current carried by the defective potassium channel complexes is impaired by reduced gating or modified channel kinetics. Because potassium channels are tetrameric proteins, there is also the potential for the presence of a single (or more) mutant subunit in a tetramer to disrupt the function of the remaining wild-type subunits (so-called dominant-negative effect) (22) (23) (24) (25) .
Mutations in the cardiac Na ϩ channels linked to LQT3 generally promote additional Na ϩ channel activity during the plateau phase of the action potential, leading to an extra component of inward current (26, 27) . This additional inward current would be expected to prolong repolarization and therefore underlie the phenotype in carriers of these SCN5A mutations (8, 28) . However, this gainof-function persistent Na ϩ current is not observed in all SCN5A mutations (29) , which implies that heterogeneity in arrhythmogenic mechanisms exists among Na ϩ channelrelated long QT syndrome (30, 31) .
CLINICAL CHARACTERISTICS
The International Long QT Syndrome Registry was started in 1979 to study epidemiologic and genetic characteristics prospectively (32-35). Among (symptomatic) probands, 50% had experienced a first cardiac event by 12 years of age, and by age 40 years the proportion had increased to almost 90% (35) . Multivariate analysis identified the following independent risk factors for syncope or sudden cardiac death: congenital deafness, history of syncope, female sex, documented torsade de pointes or ventricular fibrillation, age at first episode, and the long QT syndrome gene affected (34 -37) . The duration of the corrected QT interval (QTc) was independently associated with the risk for syncope or sudden death during follow-up (35) . These results are in line with the finding that prolongation of the QT interval in an apparently healthy population (38, 39) correlates to an increased risk for death. Whether the QTc variability over time correlates with death remains unknown (40) .
The Influence of Age and Sex
Since the duration of QT interval is shorter in men than women (41) (42) (43) (44) (45) (46) , QT prolongation could be diag- A. The ventricular action potential is initiated by current flow through cardiac Na ϩ channels (depolarization, phase 0). Early repolarization (phase 1) is caused by the K ϩ current I TO . The action potential plateau phase (phase 2) is maintained by I Ca,L , I Kr , and I Ks currents, and late repolarization (phase 3) is caused by current flow through I Ks and I K1 channels. The dotted line represents action potential prolongation, as can be observed in the congenital long QT syndrome. B. Top. In case of LQT3, most mutations in the SCN5A gene cause a small noninactivating sodium current that remains active during the action potential plateau phase (dotted line) and provides an additional depolarizing current, which prolongs repolarization. B. Middle. The KCNQ1 gene encodes the slowly activating delayed rectifier K ϩ channel, which conducts the I Ks current. In case of LQT1 (dotted line), reduced I Ks activity leads to action potential prolongation. B. Bottom. The KCNH2 gene encodes the rapidly activating delayed rectifier K ϩ channel, which conducts the I Kr current. In LQT2, a reduction of I Kr causes prolongation of the repolarization phase (dotted line).
nosed more often in women. However, after the introduction of the 1993 diagnostic criteria for the congenital long QT syndrome ( Table 1 ) that define sex-specific criteria for QT duration, such bias leading to a female predominance is less likely. Nevertheless, clinical studies consistently report a female predominance (34, 35, 45) . In men, the risk for first cardiac events is typically higher in childhood and decreases after puberty, probably because of a regression of QTc duration (42, 44, 45, 49, 50) .
The Influence of Pregnancy
Probands with the congenital long QT syndrome are at significant risk for cardiac events during the postpartum period; nearly 10% of probands in the study by Rashba and colleagues (51) experienced their first cardiac event during the postpartum period. The most important factors contributing to this risk may be related to an increase in sympathetic activity (2, 52) or to increased levels of estrogen and progesterone that directly or indirectly influence the number and function of mutant ion channel proteins (53, 54) . Treatment with ␤-blockers can reduce the risk for cardiac events (51) .
IDENTIFICATION AND MANAGEMENT OF PATIENTS WITH THE CONGENITAL LONG QT SYNDROME
Sudden death or a history of unexplained syncope in a child or young adult can bring the patient or family member to the clinician's attention. The clinician should perform electrocardiography (ECG) and interview the patient for a family history of syncope and sudden cardiac death. Many mutation carriers are asymptomatic even though they display ECG characteristics of the congenital long QT syndrome. Another group consists of individuals who have been identified as mutation carriers who do not have symptoms or ECG features (21) or intermittently display electrocardiographic signs. We recommend genetic analysis or referral to a specialized combined genetic-cardiology outpatient clinic for these patients because the study of congenital long QT mutations may improve understanding of the pathophysiology of the disease and may help to develop mutation-specific therapies in the near future (55) . In addition, a group of patients carries ion channel mutations or polymorphisms that predispose the patients to the druginduced long QT syndrome (9) . The following paragraphs discuss identification and management of these subgroups.
Patients with Symptoms of the Congenital Long QT Syndrome Symptoms
Inheritance of an affected gene is suggested by vertigo, syncopal attacks, cardiac arrest, and unexplained sudden cardiac death among immediate family members and by family members with definite long QT syndrome. Neurally mediated syncope and epileptic seizures are the most common differential diagnoses (56) . A careful history of symptoms and signs can often clarify this diagnostic dilemma.
Sudden cardiac death during sleep should also raise suspicion of the congenital long QT syndrome, particularly the LQT3 phenotype (57) .
The clinical course of the congenital long QT syndrome is largely influenced by the gene affected (36) . By age 15 years, almost 60% of patients with LQT1 have had a cardiac event (syncope, cardiac arrest, or sudden cardiac death) compared with fewer than 10% of patients with LQT3 (36, 37) . The number of cardiac events that occurred up to age 40 years was also higher in patients with LQT1 (63%) or LQT2 (46%) than in patients with LQT3 (18%). In contrast, the likelihood of death during a cardiac event was much higher in patients with LQT3 (20%) than in those with LQT1 and LQT2 (4%) (36) ( Table 2) . Because of the low number of patients, no data are yet available for patients with LQT4, LQT5, and LQT6.
Triggers for Syncopal Events
In patients with the congenital long QT syndrome, episodes of sudden loss of consciousness are almost always due to torsade de pointes arrhythmias (59) . Torsade de pointes is a polymorphic ventricular arrhythmia showing a peculiar ECG pattern characterized by a continuous twisting of the QRS axis around an imaginary baseline (60) . An important characteristic of torsade de pointes is its potential for self-termination or deterioration into ventricular fibrillation. This explains why affected patients often survive several syncopal attacks before succumbing to a fatal one. Recently it has become evident that triggers for arrhythmic episodes and syncope also depend on the specific long QT syndrome gene affected ( Table 2 ) (37, 61-63). In I Ks -related long QT syndrome (LQT1), exerciseand stress-related events dominate the clinical picture (50, 61, 64, 65) , which is related to activation of the I Ks current by adrenergic stimulation (66) . Diving and swimming, as triggers, are almost exclusive for patients with LQT1 (37, 62) . Patients with LQT3-associated Na ϩ channel mutations are at particularly high risk at rest or asleep because their QT interval is excessively prolonged at slow heart rates (65, 67) . This clear distinction between LQT1 and LQT3 with respect to exercise-related triggers does not hold for patients with LQT2, who tend to display events both at rest and during exercise (61) . However, events provoked by auditory stimuli, such as an alarm clock or telephone ringing, almost exclusively occurred in patients with LQT2 (37, 61, 62, 68, 69) . No data are yet available for patients with LQT4, LQT5, and LQT6.
Treatment Options
Symptomatic individuals require treatment (34, 35, 70) . It is important to inform patients and their parents about the importance of adherence, as nonadherence exposes patients to increased risk for cardiac events. Frequent counseling of young patients can motivate them to continue to take their medication while they are asymptomatic. On the basis of observations that physical and emotional stress are important triggers for cardiac events in patients with the congenital long QT syndrome (LQT1 and LQT2) (37, 61, 63) , nonmedical treatment should also include lifestyle advice and information on certain drugs to avoid because of their potential to prolong QT intervals. Competitive sports should be generally discouraged, but patients usually tolerate recreational sports that do not cause sudden increases in heart rate. Finally, patients are instructed on how to respond to excessive electrolyte loss, for example, during diarrhea or excessive perspiring. Patients are advised to take drinks that contain minerals, such as potassium.
␤-Blocker Therapy: Administration of ␤-blocking drugs is very effective in preventing ventricular arrhythmias in the long QT syndrome, although the response is genotype dependent (5, (71) (72) (73) (74) . The 10-year mortality rates among symptomatic patients decreased from approximately 50% in patients with the congenital long QT syndrome who were not treated to less than 5% after these patients were routinely prescribed ␤-blocker therapy (34, 35) . A recent retrospective study by Moss and colleagues (70) among 869 patients with the congenital long QT syndrome revealed a statistically significant reduction in the rate of cardiac events in both probands and affected family members after initiation of ␤-blocker therapy. In patients with aborted cardiac arrest before ␤-blocker therapy, the probability of aborted cardiac arrest or sudden death was 6.6% when ␤-blockers were used (70) . In patients with recurrent cardiac symptoms or aborted cardiac arrest, ␤-blocker therapy might not completely prevent sudden cardiac death, and implantable cardioverter defibrillator (ICD) therapy is warranted for these high-risk patients. An important criticism of this study is its retrospective nature and lack of evidence that patients continued to take their ␤-blockers. After it became clear that the congenital long QT syndrome is caused by ion channel mutations and not by imbalance of the cardiac autonomous nervous system, the rationale for performing left cardiac denervation has become less obvious. Cardiac Pacing: Because the onset of torsade de pointes arrhythmias in patients with the congenital long QT syndrome has been associated with bradycardia or pauses during sinus rhythm (75) (76) (77) , permanent cardiac pacing has been recommended as an adjuvant to ␤-blocker therapy in patients who also have bradycardia or atrioventricular conduction disturbances (78 -83) or in carriers of SCN5A mutations, who usually have slow heart rates (84, 85) . In addition, cardiac pacing can be an important adjuvant therapy in patients in whom ␤-blockers and left stellate ganglionectomy have proven inefficacious, even if bradycardia or conduction disturbances are not present (86). (58), with permission. Clinical data derived from reference 36. ϩϩϩ ϭ strong association; ϩϩ ϭ moderate association; ϩ ϭ weak association; -ϭ no effect.
Cardiac pacing should be aimed at preventing 1) bradycardia, by using a relatively high lower rate limit (Ն80 beats/ min), and 2) pauses, by using pause-prevention pacing algorithms, such as rate-smoothing. Viskin (84) reviewed applications of cardiac pacing. Implantable Cardioverter Defibrillators: Implantable cardioverter defibrillators are increasingly being used to prevent sudden cardiac death (87, 88) . Aborted sudden cardiac death and recurrent symptoms during combined ␤-blocker and pacemaker therapy are the most frequent indications for ICD implantation (87) (88) (89) . Since the ICD does not alter the underlying substrate leading to arrhythmias, initiating or continuing ␤-blocker therapy is recommended (90) .
Toward a Genotype-Specific Therapy for Symptomatic Patients: Clinical and experimental studies have recently supported the emerging sense that gene-specific therapy might be feasible for some forms of the congenital long QT syndrome. One of the first studies showed that patients with LQT3 shorten their QT interval more in response to a Na ϩ channel blocker (mexiletine) compared to patients with LQT1 and LQT2 (91) . Because most patients with LQT1 experience syncopal events during exercise, they should avoid competitive sports. As diving and swimming are particularly strong triggers for cardiac events in patients with LQT1, these activities should be strongly discouraged (37, 62, 92) . Patients with LQT2 should be advised to remove sources of loud noise from their direct environment (such as alarm clocks and telephones).
Patients with LQT1 and LQT2 genotypes typically benefit from ␤-blocker therapy (37, 70) . Because the amplitude of I Kr increases when extracellular potassium concentrations are increased (93, 94) , researchers have attempted to increase K ϩ levels in patients with LQT2 by intravenously infusing potassium or administering the diuretic spironolactone (95) . Indeed, QT intervals have been statistically significantly shortened in patients with LQT2 (96) but also in patients with LQT1 (97). Potassium supplementation is, however, hindered by difficulties in achieving sufficiently high K ϩ concentrations with longterm oral therapy (98) . On the other hand, nicorandil, a K ϩ channel opener, has normalized repolarization abnormalities induced by epinephrine infusion in patients with LQT1 (99) .
A beneficial effect of ␤-blocker therapy has not been demonstrated for patients with LQT3 (37, 70) . Since patients with LQT3 are at higher risk at slow heart rates, they may benefit from pacemaker therapy. Several clinical and experimental studies suggest a beneficial effect of Na ϩ channel blockers, such as lidocaine-mexiletine (91, 100, 101), tocainide (100), or flecainide (85) , in patients with LQT3, although long-term follow-up data are not available yet. However, flecainide may cause ECG changes reminiscent of the Brugada syndrome (familial idiopathic ventricular fibrillation) in many patients with LQT3 (102). The Brugada syndrome is characterized by right bundle-branch block and ST-segment elevation in the right precordial leads on the ECG and may lead to ventricular fibrillation and sudden cardiac death (103) . The effect of the flecainide-induced changes, which might suggest the introduction of a different arrhythmogenic substrate, is unknown. A further therapeutic differentiation based on the specific mutations in the affected gene can be expected in the near future.
Patients without Symptoms but with ECG Characteristics Suggestive of the Congenital Long QT Syndrome
Some individuals are not identified on the basis of their symptoms but because of typical electrocardiographic features suggestive of the congenital long QT syndrome. The principal diagnostic hallmark of the congenital long QT syndrome is lengthening of the QT interval on the 12-lead ECG. Because the QTc value is often not sufficiently long to make or exclude the diagnosis in borderline cases, Schwartz and colleagues (47) developed an elaborate point scoring system that goes beyond QTc duration ( Table 1) .
QT Prolongation
QT interval prolongation is usually most easily identified in leads II, V1, V3, or V5, but all 12 leads should be examined to identify the longest QT interval (104 -106) . Despite ongoing criticism, the Bazett correction formula (QTc ϭ QT/͌RR) for heart rate continues to be useful (41, 47, 104, 105) . The cut-off value commonly used was a QTc interval of 440 ms or greater, but more recent genotype-phenotype correlations indicated that greater than 460 ms was more appropriate (37, 50) . Indeed, 40% of carriers of LQT1 and LQT2 mutations show QTc values (410 -470 ms) that overlap with those of noncarriers (36, 45) . In this QTc range, phenotypic diagnosis from the ECG becomes imprecise and genetic studies help diagnose the congenital long QT syndrome. When a QTc of 460 ms or greater is used, the positive predictive accuracy for the congenital long QT syndrome is 96% in women and 91% in men; almost 100% positive predictive accuracy for the congenital long QT syndrome can be achieved at a QTc of 470 ms or greater in men and a QTc of 480 ms or greater in women (50) . Finally, QTc intervals tend to be longer in patients with LQT3 than in patients with LQT1 and LQT2 (36, 37, 45) .
QT Interval Dispersion
The second ECG characteristic is QT interval dispersion, which can be measured as a lead-to-lead variability in QT intervals (107) (108) (109) . It is debated whether this phenomenon reflects regional differences in ventricular repolarization times (110, 111) . In normal individuals, the difference between maximum and minimal QT intervals measured on the standard resting ECG has varied between 48 Ϯ 18 ms (104) and 54 Ϯ 27 ms (112) (mean Ϯ SD). In patients with the congenital long QT syndrome, how-ever, regional dispersion of ventricular repolarization times has ranged from 93 Ϯ 39 ms to 185 Ϯ 26 ms (107, 108, 112, 113) . In patients with the congenital long QT syndrome, QT dispersion may correlate with the risk for ventricular arrhythmias (107, 114) , whereas a reduction in dispersion of the QT interval could be used as a marker of therapeutic efficacy (109) .
T-Wave Structure
The congenital long QT syndrome alters not only the duration of repolarization (QT interval) but also its structure (115) . The most typical presentation of the T wave may be biphasic (116) or notched (77, 116, 117) and is most prominent in the precordial leads (116, 117) . In addition, T-wave alternans is an infrequently recorded highly arrhythmogenic ECG finding with transient beat-to-beat changes in amplitude, shape, and polarity of the T wave during sinus rhythm without concomitant QRS changes (118 -120).
Bradycardia and Sinus Pauses
Signs of sinus node dysfunction, such as sinus bradycardia or sinus pauses (72, 121, 122) , and lower-thanexpected heart rate during exercise have been reported (35, (123) (124) (125) . Slow heart rates are particularly striking in younger children (124). During submaximal exercise testing, many patients with the congenital long QT syndrome reach a heart rate lower than that achieved by healthy controls matched by sex and age (126, 127). Sinus pauses may play a role in the initiation of pause-dependent torsade de pointes arrhythmias (75, 76, 128) . The congenital long QT syndrome might also be complicated by atrioventricular conduction disturbances, which are generally associated with poor prognosis (52, 83, 125) .
Electrophysiologic Testing
Wellens and colleagues (129) performed one of the first comprehensive electrophysiologic studies in patients with the congenital long QT syndrome. The absence of inducibility by programmed stimulation indicates that the arrhythmias in the congenital long QT syndrome are probably not the result of reentrant circuits, but reentry probably plays a role in the perpetuation of torsade de pointes arrhythmias in the congenital long QT syndrome. It is therefore generally believed that electrophysiologic studies using one or more premature stimuli during ventricular pacing are of limited value in the diagnosis and treatment of patients with the congenital long QT syndrome (130, 131) . On the other hand, torsade de pointes might be inducible using short-long-short sequences (76, 132) . In addition, changes in heart rate provoked by, for example, the Valsalva maneuver or electrophysiologic protocols may lead to clear changes in the T-wave or ventricular tachycardia (77).
Response to Exercise
The standard resting ECG as a diagnostic criterion may misclassify members of families with the congenital long QT syndrome (50, 133, 134) . Therefore, an exercise test might enhance diagnostic accuracy, because shortening of the QT interval was inadequate in patients with the congenital long QT syndrome (6, 67, (135) (136) (137) (138) . In addition, a submaximal heart rate response during exercise has been reported (52, 126, 136) . Swan and colleagues (133) recently found a reduced maximum heart rate during exercise in patients with LQT1 but a normal heart rate in patients with LQT2. During recovery from exercise, patients with LQT1 showed an exaggeration of the QT interval prolongation compared with patients with LQT2 (133) . Finally, Schwartz and colleagues (91) reported that patients with LQT3 display a higher degree of QT interval shortening in response to increase in heart rate than patients with LQT2 ( Table 2) . Holter monitoring may also be useful (139) , but well-defined criteria for QTc separation of the congenital long QT syndrome from normal patients are not available. Studies have demonstrated that QT intervals up to 500 ms occur in a substantial percentage of healthy individuals (140) . Therefore, a QTc greater than 500 ms, particularly in association with T-wave abnormalities, would appear to be necessary to support the diagnosis of the congenital long QT syndrome (56) .
Genotype-Specific ECG Phenotypes in the Congenital Long QT Syndrome
The different time dependence and voltage dependence of the ionic currents involved in the congenital long QT syndrome are probably responsible for distinct ECG phenotypes that have been reported for the different genotypes. Initial studies by Moss and colleagues (36, 141) reported an association of certain T-wave patterns with LQT1, LQT2, and LQT3. Recently, Zhang and colleagues (142) recognized 10 typical ST-T wave patterns that are genotype-specific (4 LQT1, 4 LQT2, and 2 LQT3) (see Figure 2 for the most important ECG patterns). These ECG characteristics, however, cannot be used to diagnose the type of congenital long QT syndrome but are useful for selecting which gene to investigate first when performing genetic analysis.
Treatment of Asymptomatic Patients with ECG Characteristics of the Congenital Long QT Syndrome
Treatment of asymptomatic patients is still controversial because most patients with the congenital long QT syndrome will never experience symptoms (36, 37) and sudden death during the first syncopal episode is unlikely (36) . Schwartz (90) recommended that while waiting for more definitive data, physicians should begin treatment for only the following asymptomatic patients: those with congenital deafness; neonates and infants in the first year of life (because of the enhanced risk during the first months in life); siblings of children who have already died suddenly; patients with documented evidence of T-wave alternans; patients whose QTc exceeds 600 ms; and patients with manifest anxiety or patients explicitly requesting treatment.
Mutation Carriers without Symptoms or ECG Characteristics of the Congenital Long QT Syndrome
Approximately 10% of all mutation carriers have a normal QTc interval less than 440 ms (142) . However, only 2% of all carriers of the congenital long QT syndrome mutation have a normal ST-T wave pattern with a normal QT interval. Priori and colleagues (143) showed that in some families, penetrance of clinical symptoms and QT interval prolongation may be as low as 25%. This implies that family members considered normal on clinical and ECG grounds could be silent gene carriers displaying a very mild phenotype (19) . They would be unexpectedly at risk for generating affected offspring and perhaps also of developing torsade de pointes arrhythmias if exposed to either cardiac or noncardiac drugs that block potassium channels (9, 10) . Molecular screening is therefore recommended in all family members of positively genotyped patients (21) . Few patients with the congenital long QT syndrome without ECG abnormalities present with sudden death as their first symptom (105) , although preliminary data suggest that sudden death can occur in silent gene carriers (144) . Until more definitive data are available, con- servative management of silent gene carriers seems reasonable because the value of ␤-blocker therapy in this group of patients is still unknown.
Patients Carrying Mutations or Polymorphisms Associated with Drug-Provoked Long QT Syndrome
Some patients carry a predisposition for drug-induced torsade de pointes arrhythmias on the basis of the congenital long QT syndrome-related ion channel mutations (7, 97, 145) . These patients are usually clinically asymptomatic until administration of a drug. A genetic predisposition to drug-provoked long QT syndrome torsade de pointes can be caused by mutations in the KCNE2 subunit of the I Kr potassium channel (16, 146) or a mutation in the KCNQ1 subunit of the I Ks channel (10, 147) ( Table 3 ). In addition, a polymorphism in the KCNE1 gene (148), as well as two relatively common polymorphisms in KCNE2 (allelic frequency in both cases around 1.6%), has been associated with quinidine-and erythromycin-induced long QT syndrome (9, 16) . Drug-provoked long QT syndrome has also been linked to a mutation in SCN5A (149) . In 34 patients with drug-induced long QT syndrome, we detected two previously described mutations in ion channels. None of the additional polymorphisms resulted in amino acid changes in ion channel proteins (Doevendans and colleagues. Personal communication).
However, in most patients with the acquired long QT syndrome (Ͼ85%), no ion channel mutations have been identified thus far. In this case, the acquired long QT syndrome is thought to result from electrolyte disturbances; hypertrophy; or treatment with commonly used medications, including some antiarrhythmic, antihistamine, antibiotic, psychoactive, and gastrointestinal prokinetic agents (150) . In patients without ion channel mutations, proarrhythmia is probably induced by block of the potassium current I Kr (151) . Recent studies have clarified why so many structurally diverse compounds block KCNH2 channels but not other potassium channels. Because the KCNH2 channel has a unique group of amino acids in the S6 domain that are not present in other voltage-gated K ϩ channels (Kv1 to Kv4), many drugs preferentially block KCNH2 channels (9) , placing patients at risk for cardiac arrhythmias. The acquired long QT syndrome occurs more often in females (152) .
Genetic diagnostic approaches in patients with the acquired long QT syndrome should be restricted to centers with sufficient experience in the genetic identification of these patients. The relevance of the polymorphisms is not clear yet, and there is no well-defined set of genes that have to be analyzed. A pragmatic approach is to provide a list of compounds that should not be used in the future and should be known to both mutation carriers and patients with the congenital long QT syndrome.
SUMMARY
The congenital long QT syndrome is a potentially lifethreatening condition characterized clinically by prolonged QT intervals, syncope, and sudden cardiac death. The abnormally prolonged repolarization is the result of mutations in genes encoding cardiac ion channels. The diagnosis of the congenital long QT syndrome is based on clinical, ECG, and genetic criteria. ␤-Blocker therapy is important in the treatment of the congenital long QT syndrome, although pacemakers and ICDs are useful for some patients. In the near future, mutation-specific treatment will probably become a novel approach to this potentially fatal syndrome. 
